Two-stage flux balance analysis of metabolic networks for drug target identification

BMC Systems Biology

Volumn 5, Issue SUPPL. 1, 2011, Pages

  Li, Zhenping ^a   Wang, Rui Sheng ^b   Zhang, Xiang Sun ^c  

^a BEIJING WUZI UNIVERSITY   (China)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; BIOLOGY; DRUG DEVELOPMENT; HUMAN; HYPERURICEMIA; METABOLISM; METHODOLOGY; PROTEIN BINDING;

COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HUMANS; HYPERURICEMIA; METABOLIC NETWORKS AND PATHWAYS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 79959223999     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-5-S1-S11     Document Type: Article

References (42)

1. Smith C. Drug target validation: Hitting the target. Nature 2003, 422:341-347.
2. Smith C. Drug target identification: A question of biology. Nature 2004, 428:225-231. 10.1038/428225a, 15014515.
3. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. The New England Journal of Medicine 2003, 348(6):538-549. 10.1056/NEJMra020526, 12571262.
4. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008, 321:263-266. 10.1126/science.1158140, 18621671.
5. Kell DB. Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discovery Today 2006, 11:1085-1092. 10.1016/j.drudis.2006.10.004, 17129827.
6. Guimerà R, Sales-Pardo M, Amaral LAN. A network-based method for target selection in metabolic networks. Bioinformatics 2007, 23:1616-1622. 10.1093/bioinformatics/btm150, 2149892, 17463022.
7. Vera J, Curto R, Cascante M, Torres NV. Detection of potential enzyme targets by metabolic modelling and optimization: Application to a simple enzymopathy. Bioinformatics 2007, 23:2281-2289. 10.1093/bioinformatics/btm326, 17586544.
8. Hormozdiari F, Salari R, Bafna V, Sahinalp SC. Protein-protein interaction network evaluation for identifying potential drug targets. Journal of Computational Biology 2010, 17(5):669-684. 10.1089/cmb.2009.0032, 20500021.
9. Kushwaha SK, Shakya M. Protein interaction network analysis-approach for potential drug target identification in Mycobacterium tuberculosis. Journal Theoretical Biology 2010, 262:284-294.
10. Karlebach G, Shamir R. Minimally perturbing a gene regulatory network to avoid a disease phenotype: the glioma network as a test case. BMC Systems Biology 2010, 4:15. 10.1186/1752-0509-4-15, 2851584, 20184733.
11. Bleakely K, Yamanishi Y. Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics 2009, 25:2397-2403. 10.1093/bioinformatics/btp433, 2735674, 19605421.
12. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008, 24:i232-i240. 10.1093/bioinformatics/btn162, 2718640, 18586719.
13. Yamanishi Y, Kotera M, Kanehisa M, Goto S. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 2010, 26:i246-i254. 10.1093/bioinformatics/btq176, 2881361, 20529913.
14. Klipp E, Wade RC, Kummer U. Biochemical network-based durg-target prediction. Current Opinion in Biotechnology 2010, 21:1-6. 10.1016/j.copbio.2010.05.004, 20189376.
15. Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Neglected 2010, 4(8):e804. Tropical Diseases.
16. Ozbayraktar FB, Ulgen KO. Drug target identification in sphingolipid metabolism by computational systems biology tools: metabolic control analysis and metabolic pathway analysis. Journal of Biomedical Informatics 2010, 43(4):537-549. 10.1016/j.jbi.2010.03.006, 20348024.
17. Strong M, Eisenberg D. The protein network as a tool for finding novel drug targets. Progress in Drug Research 2007, 64:191-215. full_text, 17195476.
18. Raman K, Rajagopalan P, Chandra N. Flux balance analysis of mycolic acid pathway: targets for anti-tubercular drugs. 2005, 1(5):e46. PLoS Computational Biology.
19. Kim HK, Kim TY, Lee SY. Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE. Molecular BioSystems 2010, 6(2):339-348. 10.1039/b916446d, 20094653.
20. Plata G, Hsiao TL, Olszewski KL, Linás M, Vitkup D. Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network. Molecular Systems Biology 2010, 6:408. 10.1038/msb.2010.60, 2964117, 20823846.
21. Ma H, Goryanin. Human metabolic network reconstruction and its impact on drug discovery and development. Drug Discovery Today 2008, 13:402-408. 10.1016/j.drudis.2008.02.002, 18468557.
22. Li L, Zhou X, Ching WK, Wang P. Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines. BMC Bioinformatics 2010, 11:501. 2964682, 20932284.
23. Sridhar P, Kahveciy T, Ranka S. An iterative algorithm for metabolic network-based drug target identification. Pacific Symposium on Biocomputing 2007, 12:88-99.
24. Sridhar P, Song B, Kahveciy T, Ranka S. Mining metabolic network for optimal drug targets. Pacific Symposium on Biocomputing 2008, 13:291-302.
25. Song B, Sridhar P, Kahveci T, Ranka S. Double iterative optimisation for metabolic network-based drug target identification. International Journal of Data Mining and Bioinformatics 2009, 3(2):124-144. 10.1504/IJDMB.2009.024847, 19517985.
26. Li Z, Wang RS, Zhang XS, Chen L. Detecting drug targets with minimum side effects in metabolic networks. IET Systems Biology 2009, 3(6):523-533. 10.1049/iet-syb.2008.0166, 19947778.
27. Wang RS, Li Z, Zhang XS, Chen L. Optimization and control of metabolic networks. In Proceedings of the 29th Chinese Control Conference: 29-31 July 2010; Beijing 2010, 6251-6255.
28. Cascante M, Boros LG, Comin-Anduix B, de Atauri P, Centelles JJ, Lee PW. Metabolic control analysis in drug discovery and disease. Nature Biotechnology 2002, 20(3):243-249. 10.1038/nbt0302-243, 11875424.
29. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabási AL. The large-scale organization of metabolic networks. Nature 2000, 407:652-654.
30. Varma A, Palsson B. Metabolic flux balancing: Basic concepts, scientific and practical use. Bio/Technology 1994, 12:994-998.
31. Raman K, Chandra N. Flux balance analysis of biological systems: applications and challenges. Briefings in Bioinformatics 2009, 10(4):435-449. 10.1093/bib/bbp011, 19287049.
32. Oberhardt MA, Chavali AK, Papin JA. Flux balance analysis: interrogating genome-scale metabolic networks. Methods in Molecular Biology 2009, 500:61-80. full_text, 19399432.
33. Chu LH, Chen BS. Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets. BMC Systems Biology 2008, 2:56. 10.1186/1752-0509-2-56, 2488323, 18590547.
34. De RK, Das M, Mukhopadhyay S. Incorporation of enzyme concentrations into FBA and identification of optimal metabolic pathways. BMC Systems Biology 2008, 2:65. 10.1186/1752-0509-2-65, 2533768, 18634554.
35. Brulé D, Sarwar G, Savoie L. Changes in serum and urinary uric acid levels in normal human subjects fed purine-rich foods containing different amounts of adenine and hypoxanthine. Journal of the American College of Nutrition 1992, 11(3):353-358.
36. Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic basis of inherited disease,. 1989, New York: McGraw-Hill, 6th.
37. Curto R, Voit EO, Cascante M. Analysis of abnormalities in purine metabolism leading to gout and to neurological dysfunctions in man. Biochemical Journal 1998, 329:477-487. 1219067, 9445373.
38. Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xantine oxidase inhibitor allopurinol in the treatment of gout. Ann. Intern. Med 1965, 62:639-647.
39. Kim PJ, Lee DY, Kim TY, Lee KH, Jeong H, Lee SY, Park S. Metabolite essentiality elucidates robustness of Escherichia coli metabolism. Proc Natl Acad Sci USA 2007, 104:13638-13642. 10.1073/pnas.0703262104, 1947999, 17698812.
40. Chung BKS, Lee DY. Flux-sum analysis: a metabolite-centric approach for understanding the metabolic network. BMC Systems Biology 2009, 3:117. 10.1186/1752-0509-3-117, 2805632, 20021680.
41. Kim TY, Kim HU, Lee SY. Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. Metabolic Engineering 2010, 12(2):105-111. 10.1016/j.ymben.2009.05.004, 19481614.
42. Shlomi T, Cabili MN, Ruppin E. Predicting metabolic biomarkers of human inborn errors of metabolism. Molecular Systems Biology 2009, 5:263. 10.1038/msb.2009.22, 2683725, 19401675.